What is AgeneBio?
AgeneBio operates at the intersection of advanced neuroscience and pharmaceutical innovation, focusing on the development of therapeutics designed to mitigate the progression of Alzheimer's dementia and related cognitive impairments. The company's core competency lies in its late-stage clinical programs, which target the underlying mechanisms of neurodegeneration. By addressing conditions such as mild cognitive impairment, autism, and schizophrenia, AgeneBio occupies a high-barrier-to-entry niche within the life sciences market. Their commitment to evidence-based therapeutic advancements positions them as a key contributor to the global effort to improve patient outcomes in the face of complex brain-related disorders.
How much funding has AgeneBio raised?
AgeneBio has raised a total of $17.8M across 6 funding rounds:
Debt
$3.7M
Other Financing Round
$1M
Other Financing Round
$1M
Private Equity
$4.1M
Grant
$7.5M
Grant
$500K
Debt (2010): $3.7M, investors not publicly disclosed
Other Financing Round (2013): $1M, investors not publicly disclosed
Other Financing Round (2013): $1M, investors not publicly disclosed
Private Equity (2014): $4.1M, investors not publicly disclosed
Grant (2015): $7.5M backed by National Institutes of Health
Grant (2019): $500K with participation from The Alzheimer's Drug Discovery Foundation
Key Investors in AgeneBio
National Institutes of Health
The National Institutes of Health is the primary agency of the United States government responsible for biomedical and health-related research, providing critical grant support for high-impact medical innovation.
The Alzheimer's Drug Discovery Foundation
A specialized philanthropic organization dedicated to accelerating the discovery and development of innovative drugs to treat, prevent, and cure Alzheimer's disease.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for AgeneBio?
Looking ahead, AgeneBio is poised to leverage its recent capital injection to transition from clinical development toward potential commercialization milestones. The strategic focus will likely remain on the successful execution of its late-stage clinical trials, which are essential for regulatory approval and long-term market viability. Investors and stakeholders are closely monitoring the company's ability to translate its research-driven insights into scalable therapeutic solutions. As the firm continues to navigate the regulatory landscape, the emphasis will be on maintaining operational efficiency and securing the necessary partnerships to bring its innovative treatments to the global market, thereby solidifying its competitive advantage in the neuro-therapeutics space.
See full AgeneBio company page
